Class Says FDA Ruling Backs Nexium Pay-For-Delay Retrial
On the heels of losing a pay-for-delay trial against Ranbaxy Pharmaceuticals Inc. and AstraZeneca PLC over generic Nexium, class plaintiffs contended Thursday that a recent U.S. Food and Drug Administration decision...To view the full article, register now.
Already a subscriber? Click here to view full article